BiotechTube

buntanetap/posiphen + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease, Idiopathic

Conditions

Parkinson's Disease, Idiopathic

Trial Timeline

Aug 3, 2022 → Dec 4, 2023

NCT ID
NCT05357989

About buntanetap/posiphen + Placebo

buntanetap/posiphen + Placebo is a phase 3 stage product being developed by Annovis Bio for Parkinson's Disease, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT05357989. Target conditions include Parkinson's Disease, Idiopathic.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT06709014Phase 3Recruiting
NCT05686044Phase 2/3Completed
NCT05357989Phase 3Completed

Competing Products

20 competing products in Parkinson's Disease, Idiopathic

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
perampanel + placeboEisaiPhase 2
52
Lemborexant + placeboEisaiApproved
85
Placebo + E2007 + E2007EisaiPhase 3
77
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 3
77

Other Products from Annovis Bio

buntanetap/posiphen + PlaceboPhase 3
69
Buntanetap/Posiphen + PlaceboPhase 2/3
57
buntanetap/posiphenPhase 2/3
57
Posiphen + PlaceboPhase 1/2
33
Posiphen + PlaceboPhase 1/2
33